SHR7280 tablets + SHR7280 tablets + PlaceboSHR7280 tablets blank preparation
Phase 2/3Recruiting 0 views this week 0 watching⚡ Active
Interest: 45/100
45
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Uterine Fibroids With Menorrhagia
Conditions
Uterine Fibroids With Menorrhagia
Trial Timeline
Sep 10, 2022 → Jun 1, 2026
NCT ID
NCT05442827About SHR7280 tablets + SHR7280 tablets + PlaceboSHR7280 tablets blank preparation
SHR7280 tablets + SHR7280 tablets + PlaceboSHR7280 tablets blank preparation is a phase 2/3 stage product being developed by Jiangsu Hengrui Medicine for Uterine Fibroids With Menorrhagia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05442827. Target conditions include Uterine Fibroids With Menorrhagia.
What happened to similar drugs?
4 of 18 similar drugs in Uterine Fibroids With Menorrhagia were approved
Approved (4) Terminated (7) Active (8)
Hype Score Breakdown
Clinical
15
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05442827 | Phase 2/3 | Recruiting |
Competing Products
20 competing products in Uterine Fibroids With Menorrhagia